Clinical Policy: Erdafitinib (Balversa)
Reference Number: CP.PHAR.423
Effective Date: 05.07.19
Last Review Date: 08.20
Line of Business: Commercial, HIM, Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Erdafitinib (Balversa™) is a fibroblast growth factor receptor (FGFR) kinase inhibitor.

FDA Approved Indication(s)
Balversa is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has:
- susceptible FGFR3 or FGFR2 genetic alterations and
- progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Select patients for therapy based on an FDA-approved companion diagnostic for Balversa.

This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Balversa is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Urothelial Carcinoma (must meet all):
      1. Diagnosis of recurrent, locally advanced, or metastatic urothelial carcinoma;
      2. Prescribed by or in consultation with an oncologist;
      3. Age ≥ 18 years;
      4. Presence of susceptible FGFR3 or FGFR2 genetic alterations (see Appendix D);
      5. Prescribed as subsequent therapy following platinum-containing chemotherapy (e.g., cisplatin, carboplatin) or checkpoint inhibitor therapy (e.g., Tecentriq®, Keytruda®) (see Appendix B);
      *Prior authorization may be required for platinum-containing chemotherapy, Tecentriq, and Keytruda
      6. Request meets one of the following (a or b):
         a. Dose does not exceed 9 mg (3 tablets) per day;
         b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
      *Prescribed regimen must be FDA-approved or recommended by NCCN
Approval duration:
Medicaid/HIM – 6 months
Commercial – Length of Benefit

B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy
A. Urothelial Carcinoma (must meet all):
1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Balversa for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):
   a. New dose does not exceed 9 mg (3 tablets) per day;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:
Medicaid/HIM – 12 months
Commercial – Length of Benefit

B. Other diagnoses/indications (must meet 1 or 2):
1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
FGFR: fibroblast growth factor receptor
NCCN: National Comprehensive Cancer Network
**Appendix B: Therapeutic Alternatives**

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>carboplatin</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>cisplatin</td>
<td>Varies</td>
<td>Varies</td>
</tr>
<tr>
<td>Tecentriq (atezolizumab)</td>
<td>UC (labeled use for locally advanced or metastatic disease): 840 mg IV once every 2 weeks or 1,200 mg once every 3 weeks or 1,680 mg once every 4 weeks.</td>
<td>Varies</td>
</tr>
<tr>
<td>Keytruda (pembrolizumab)</td>
<td>UC (labeled use for locally advanced or metastatic disease): 200 mg IV once every 3 weeks until disease progression, unacceptable toxicity, or (in patients without disease progression) for up to 24 months.</td>
<td>200 mg/3 weeks</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

**Appendix C: Contraindications/Boxed Warnings**

None reported

**Appendix D: General Information**

- The presence of FGFR genetic alterations should be confirmed prior to initiation of treatment with Balversa. Patients with at least 1 of the following genetic alterations: FGFR3 gene mutations (R248C, S249C, G370C, Y373C) or FGFR gene fusions (FGFR3-TACC3, FGFR3-BAIAP2L1, FGFR2-BICC1, FGFR2-CASP7) were included in the clinical study for approval.
- Information on FDA-approved tests for the detection of FGFR genetic alterations in urothelial carcinoma is available at: [http://www.fda.gov/CompanionDiagnostics](http://www.fda.gov/CompanionDiagnostics).

**V. Dosage and Administration**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urothelial carcinoma</td>
<td>8 mg (two 4 mg tablets) PO QD with a dose increase to 9 mg (three 3 mg tablets) QD if serum phosphate level is &lt; 5.5 mg/dL at 14-21 days and there are no ocular disorders or Grade 2 or greater adverse reactions</td>
<td>9 mg/day</td>
</tr>
</tbody>
</table>

**VI. Product Availability**

Tablets: 3 mg, 4 mg, 5 mg

**VII. References**


<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>05.07.19</td>
<td>08.19</td>
</tr>
<tr>
<td>Finalized line of businesses on policy to include HIM per SDC and prior clinical guidance.</td>
<td>10.07.19</td>
<td></td>
</tr>
<tr>
<td>3Q 2020 annual review: recurrent disease and checkpoint inhibitor prior therapy option added per NCCN; references reviewed and updated.</td>
<td>05.12.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise
professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.